Tempest Therapeutics TPST Stock
Tempest Therapeutics Price Chart
Tempest Therapeutics TPST Financial and Trading Overview
| Tempest Therapeutics stock price | 1.26 USD |
| Previous Close | 1.23 USD |
| Open | 1.25 USD |
| Bid | 0.91 USD x 200 |
| Ask | 1.6 USD x 200 |
| Day's Range | 1.23 - 1.3 USD |
| 52 Week Range | 1.22 - 12.23 USD |
| Volume | 28.15K USD |
| Avg. Volume | 200.44K USD |
| Market Cap | 18.51M USD |
| Beta (5Y Monthly) | -1.781 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.7 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11 USD |
TPST Valuation Measures
| Enterprise Value | 24.56M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.0330578 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 21.929825 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.174 |
Trading Information
Tempest Therapeutics Stock Price History
| Beta (5Y Monthly) | -1.781 |
| 52-Week Change | -82.24% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 12.23 USD |
| 52 Week Low | 1.22 USD |
| 50-Day Moving Average | 1.72 USD |
| 200-Day Moving Average | 4.43 USD |
TPST Share Statistics
| Avg. Volume (3 month) | 200.44K USD |
| Avg. Daily Volume (10-Days) | 53.2K USD |
| Shares Outstanding | 14.81M |
| Float | 9.57M |
| Short Ratio | 2.52 |
| % Held by Insiders | 34.30% |
| % Held by Institutions | 28.48% |
| Shares Short | 341.33K |
| Short % of Float | 5.41% |
| Short % of Shares Outstanding | 2.31% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:13 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -61.68% |
| Return on Equity (ttm) | -721.0040% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -20920000 USD |
| Net Income Avi to Common (ttm) | -43098000 USD |
| Diluted EPS (ttm) | -5.7 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.81M USD |
| Total Cash Per Share (mrq) | 0.12 USD |
| Total Debt (mrq) | 7.85M USD |
| Total Debt/Equity (mrq) | 955.47 USD |
| Current Ratio (mrq) | 0.739 |
| Book Value Per Share (mrq) | 0.057 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -26382000 USD |
| Levered Free Cash Flow (ttm) | -16625000 USD |
Profile of Tempest Therapeutics
| Country | United States |
| State | CA |
| City | Brisbane |
| Address | 2000 Sierra Point Parkway |
| ZIP | 94005 |
| Phone | 415 798 8589 |
| Website | https://www.tempesttx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 5 |
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Q&A For Tempest Therapeutics Stock
What is a current TPST stock price?
Tempest Therapeutics TPST stock price today per share is 1.26 USD.
How to purchase Tempest Therapeutics stock?
You can buy TPST shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tempest Therapeutics?
The stock symbol or ticker of Tempest Therapeutics is TPST.
Which industry does the Tempest Therapeutics company belong to?
The Tempest Therapeutics industry is Biotechnology.
How many shares does Tempest Therapeutics have in circulation?
The max supply of Tempest Therapeutics shares is 14.81M.
What is Tempest Therapeutics Price to Earnings Ratio (PE Ratio)?
Tempest Therapeutics PE Ratio is now.
What was Tempest Therapeutics earnings per share over the trailing 12 months (TTM)?
Tempest Therapeutics EPS is -5.7 USD over the trailing 12 months.
Which sector does the Tempest Therapeutics company belong to?
The Tempest Therapeutics sector is Healthcare.
Tempest Therapeutics TPST included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}